• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Dietary Phosphorus as a Marker of Mineral Metabolism and Progression of Diabetic Kidney Disease.膳食磷作为矿物质代谢和糖尿病肾病进展的标志物。
Nutrients. 2021 Feb 27;13(3):789. doi: 10.3390/nu13030789.
2
Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease.中国慢性肾脏病患者的矿物质与骨代谢紊乱及其与心血管参数的关联
Chin Med J (Engl). 2016 Oct 5;129(19):2275-80. doi: 10.4103/0366-6999.190678.
3
Management of phosphorus load in CKD patients.慢性肾脏病患者磷负荷的管理。
Clin Exp Nephrol. 2017 Mar;21(Suppl 1):27-36. doi: 10.1007/s10157-016-1360-y. Epub 2016 Nov 28.
4
The challenge of controlling phosphorus in chronic kidney disease.慢性肾脏病中磷的控制难题。
Nephrol Dial Transplant. 2016 Apr;31(4):541-7. doi: 10.1093/ndt/gfv055. Epub 2015 Mar 13.
5
Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.慢性肾脏病/终末期肾病中磷代谢紊乱:治疗考虑。
Adv Chronic Kidney Dis. 2011 Mar;18(2):120-31. doi: 10.1053/j.ackd.2011.02.004.
6
The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease.磷结合药物和低膳食磷蛋白比值在降低慢性肾脏病患者肠道磷负荷中的作用。
Nutr Diabetes. 2019 Apr 3;9(1):14. doi: 10.1038/s41387-019-0080-2.
7
Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder.二甲双胍可预防严重慢性肾脏病及其相关矿物质和骨代谢紊乱的发生。
Kidney Int. 2018 Jul;94(1):102-113. doi: 10.1016/j.kint.2018.01.027. Epub 2018 Apr 30.
8
[Diabetic Kidney Disease 3rd stage - laboratory markers of mineral bone disorder].[糖尿病肾病3期——矿物质骨代谢紊乱的实验室指标]
Vnitr Lek. 2016 Summer;62(6):442-8.
9
Phosphate, Microbiota and CKD.磷酸盐、微生物群与慢性肾脏病。
Nutrients. 2021 Apr 13;13(4):1273. doi: 10.3390/nu13041273.
10
Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease.开发一种新型慢性肾脏病小鼠模型,以评估高磷血症及其相关矿物质骨病的进展情况。
Sci Rep. 2017 May 22;7(1):2233. doi: 10.1038/s41598-017-02351-6.

引用本文的文献

1
Association between serum uric acid to high-density lipoprotein cholesterol ratio (UHR) and abdominal aortic calcification: a cross-sectional study based on NHANES 2013-2014.血清尿酸与高密度脂蛋白胆固醇比值(UHR)与腹主动脉钙化之间的关联:一项基于2013 - 2014年美国国家健康与营养检查调查(NHANES)的横断面研究。
Front Cardiovasc Med. 2025 May 29;12:1560022. doi: 10.3389/fcvm.2025.1560022. eCollection 2025.
2
Relationship between bone turnover markers and renal disease in elderly patients with type 2 diabetes: a cross-sectional study.老年 2 型糖尿病患者骨转换标志物与肾脏疾病的关系:一项横断面研究。
BMC Endocr Disord. 2024 Sep 6;24(1):179. doi: 10.1186/s12902-024-01698-y.
3
Hydrogel-based Drug Delivery System in Diabetes Management.水凝胶基药物输送系统在糖尿病管理中的应用。
Pharm Nanotechnol. 2024;12(4):289-299. doi: 10.2174/0122117385266276230928064235.
4
Phosphate Dysregulation and Metabolic Syndrome.磷酸盐失调与代谢综合征。
Nutrients. 2022 Oct 25;14(21):4477. doi: 10.3390/nu14214477.
5
Vitamin D with Calcium Supplementation Managing Glycemic Control with HbA1c and Improve Quality of Life in Patients with Diabetes.补充维生素D和钙可通过糖化血红蛋白控制血糖,并改善糖尿病患者的生活质量。
Turk J Pharm Sci. 2022 Apr 29;19(2):161-167. doi: 10.4274/tjps.galenos.2021.62357.
6
A long non-coding RNA H19/microRNA-138/TLR3 network is involved in high phosphorus-mediated vascular calcification and chronic kidney disease.长链非编码 RNA H19/miR-138/TLR3 网络参与高磷介导的血管钙化和慢性肾脏病。
Cell Cycle. 2022 Aug;21(16):1667-1683. doi: 10.1080/15384101.2022.2064957. Epub 2022 Apr 18.

本文引用的文献

1
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.达格列净对伴有和不伴有糖尿病的慢性肾脏病患者的主要不良肾脏和心血管事件的影响:来自 DAPA-CKD 试验的预先指定分析。
Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7.
2
Introduction: .引言:.
Diabetes Care. 2021 Jan;44(Suppl 1):S1-S2. doi: 10.2337/dc21-Sint.
3
Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000-2015.2000 - 2015年全球糖尿病相关终末期肾病流行病学
Diabetes Care. 2021 Jan;44(1):89-97. doi: 10.2337/dc20-1913. Epub 2020 Nov 17.
4
Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection.SGLT2 抑制剂对心肾保护的分子机制。
Int J Mol Sci. 2020 Oct 22;21(21):7833. doi: 10.3390/ijms21217833.
5
Importance of Dietary Phosphorus for Bone Metabolism and Healthy Aging.饮食磷对骨骼代谢和健康老龄化的重要性。
Nutrients. 2020 Sep 30;12(10):3001. doi: 10.3390/nu12103001.
6
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.KDIGO 2020慢性肾脏病糖尿病管理临床实践指南
Kidney Int. 2020 Oct;98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019.
7
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
8
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
9
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.达格列净与慢性肾脏病不良结局预防(DAPA-CKD)试验:基线特征。
Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711. doi: 10.1093/ndt/gfaa234.
10
Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update.慢性肾脏病中的内皮功能障碍:从生物学机制到临床结局——2020年更新
J Clin Med. 2020 Jul 23;9(8):2359. doi: 10.3390/jcm9082359.

膳食磷作为矿物质代谢和糖尿病肾病进展的标志物。

Dietary Phosphorus as a Marker of Mineral Metabolism and Progression of Diabetic Kidney Disease.

机构信息

Department of Nephrology, Hypertension and Internal Medicine, University of Warmia and Mazury in Olsztyn,10561 Olsztyn, Poland.

出版信息

Nutrients. 2021 Feb 27;13(3):789. doi: 10.3390/nu13030789.

DOI:10.3390/nu13030789
PMID:33673618
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7997399/
Abstract

Phosphorus is an essential nutrient that is critically important in the control of cell and tissue function and body homeostasis. Phosphorus excess may result in severe adverse medical consequences. The most apparent is an impact on cardiovascular (CV) disease, mainly through the ability of phosphate to change the phenotype of vascular smooth muscle cells and its contribution to pathologic vascular, valvular and other soft tissue calcification. Chronic kidney disease (CKD) is the most prevalent chronic disease manifesting with the persistent derangement of phosphate homeostasis. Diabetes and resulting diabetic kidney disease (DKD) remain the leading causes of CKD and end-stage kidney disease (ESRD) worldwide. Mineral and bone disorders of CKD (CKD-MBD), profound derangement of mineral metabolism, develop in the course of the disease and adversely impact on bone health and the CV system. In this review we aimed to discuss the data concerning CKD-MBD in patients with diabetes and to analyze the possible link between hyperphosphatemia, certain biomarkers of CKD-MBD and high dietary phosphate intake on prognosis in patients with diabetes and DKD. We also attempted to clarify if hyperphosphatemia and high phosphorus intake may impact the onset and progression of DKD. Careful analysis of the available literature brings us to the conclusion that, as for today, no clear recommendations based on the firm clinical data can be provided in terms of phosphorus intake aiming to prevent the incidence or progression of diabetic kidney disease.

摘要

磷是一种必需的营养物质,对于控制细胞和组织功能以及体内平衡至关重要。磷过量可能导致严重的不良医学后果。最明显的是对心血管(CV)疾病的影响,主要是通过磷酸盐改变血管平滑肌细胞表型及其对病理性血管、瓣膜和其他软组织钙化的贡献。慢性肾脏病(CKD)是最常见的慢性疾病,表现为磷稳态持续失调。糖尿病和由此导致的糖尿病肾病(DKD)仍然是全球 CKD 和终末期肾病(ESRD)的主要原因。矿物质和骨代谢紊乱的 CKD(CKD-MBD),即矿物质代谢的严重失调,在疾病过程中发展,并对骨骼健康和心血管系统产生不利影响。在这篇综述中,我们旨在讨论糖尿病患者 CKD-MBD 的相关数据,并分析高磷血症、某些 CKD-MBD 生物标志物与高膳食磷摄入与糖尿病和 DKD 患者预后之间的可能联系。我们还试图阐明高磷血症和高磷摄入是否会影响 DKD 的发生和进展。对现有文献的仔细分析使我们得出结论,就目前而言,基于确凿的临床数据,无法提供针对磷摄入的明确建议,以预防糖尿病肾病的发生或进展。